Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Retatrutide: Evidence Summary
Evidence summary for Retatrutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Retatrutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Weight loss (obesity) | Tier B | 2 | Phase II trial showed up to 24% body weight reduction at 48 weeks — Phase III ongoing |
| Type 2 diabetes | Tier B | 2 | Significant HbA1c reduction in Phase II; triple agonism provides metabolic benefits |